Jonathan Mark Hopper - 02 Apr 2026 Form 4 Insider Report for Vericel Corp (VCEL)

Reporting relationship: Chief Medical Officer
Issuer ticker: VCEL
Reported as of: 02 Apr 2026
Net transaction value: -$121,520
SEC form: 4
Accepted by SEC: 06 Apr 2026, 16:05:42 UTC
Prior SEC filing: 26 Feb 2026
Next SEC filing: 04 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Sean Flynn, as Attorney-in-Fact for Jonathan Hopper

Key filing fact

Jonathan Mark Hopper filed Form 4 for Vericel Corp (VCEL) on 06 Apr 2026.

Key facts

This page summarizes Jonathan Mark Hopper's Form 4 filing for Vericel Corp (VCEL).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 06 Apr 2026, 16:05.

Change

Previous filing in this sequence was filed on 26 Feb 2026.
Current net transaction value: -$121,520.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001626325 Primary reporting owner

Hopper Jonathan Mark

Relationship: Chief Medical Officer
Address: 64 SIDNEY STREET, CAMBRIDGE
Signature: /s/ Sean Flynn, as Attorney-in-Fact for Jonathan Hopper
Signature date: 06 Apr 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

VCEL transaction

Common Stock

Options Exercise

Transaction value
Shares: +3,472
Change %: +4.6%
Price: $10.95^*
Shares after: 79,028
Date: 02 Apr 2026
Ownership: Direct
Footnotes: F1

VCEL transaction

Common Stock

Sale

Transaction value: $121,520
Shares: -3,472
Change %: -4.4%
Price: $35.00
Shares after: 75,556
Date: 02 Apr 2026
Ownership: Direct
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

VCEL transaction Derivative

Stock Option (Right to Buy)

Options Exercise

Transaction value
Shares: +3,472
Change %: +61%
Price: $0.000000^*
Shares after: 9,132
Date: 02 Apr 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 3,472
Exercise price: $10.95
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 3 footnotes

Footnote F1

These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).

Footnote F2

The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 30, 2025.

Footnote F3

These options, representing the right to purchase 135,000 shares, became exercisable on August 20, 2019, the first anniversary of the date of grant, with 25% vesting and the remaining 75% vesting in equal quarterly installments over three years thereafter, contingent upon continued service to the Company.